Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo

Inclusion Criteria: * Clinical diagnosis of non-segmental vitiligo (NSV) and no segmental or localized vitiligo. * Participants with all of the following at Screening and Baseline. * Visits: ≥ 0.5 F-VASI and ≥ 5 total vitiligo area scoring index (T-VASI). * Participants who have had prior exposure to immunomodulatory biologic therapy, for any indications, but discontinued the biologic therapy prior to the first dose of study drug. Recommended washout periods for biologic therapies include ≥ 4 weeks for etanercept; ≥ 8 weeks for adalimumab, infliximab, certolizumab, golimumab, abatacept, tocilizumab, and ixekizumab; ≥ 16 weeks for secukinumab; and ≥ 12 weeks for ustekinumab. For biologic therapies not specified, therapies must be discontinued at least 5 times the mean terminal elimination half-life of a drug or 3 months prior to Baseline, whichever is longer. Exclusion Criteria: * Participants with segmental or localized vitiligo. * Participants with other skin conditions that would interfere with evaluation of vitiligo, participants with uncontrolled thyroid disease, and participants with \> 33% leukotrichia on the face or \> 33% leukotrichia on the body (including face). * Participants previously treated with any topical or systemic janus kinase (JAK) inhibitor or permanent skin bleaching agents. * Participants treated with any systemic vitiligo therapy (e.g., methotrexate, mycophenolate mofetil, corticosteroids), supplemental vitiligo therapy (antioxidants/vitamins/…